Last reviewed · How we verify

Dexmedetomidine 0.5 mic/kg

Al-Azhar University · Phase 3 active Small molecule

Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.

Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Sedation in intensive care unit patients, Perioperative sedation and analgesia, Sedation during mechanical ventilation.

At a glance

Generic nameDexmedetomidine 0.5 mic/kg
SponsorAl-Azhar University
Drug classAlpha-2 adrenergic agonist
TargetAlpha-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaAnesthesia and Sedation
PhasePhase 3

Mechanism of action

Dexmedetomidine binds with high selectivity to alpha-2 adrenergic receptors, particularly in the locus coeruleus and other brainstem regions, leading to inhibition of norepinephrine release and reduced neuronal firing. This results in a unique sedative state characterized by maintained airway reflexes and the ability to be aroused, along with analgesic and anxiolytic effects. The drug produces dose-dependent sedation without significant respiratory depression at clinical doses.

Approved indications

Common side effects